Latest Commercialisation News

Strategic Elements Ltd (ASX: SOR) reported meaningful progress in its Energy Ink™ technology and underground mining platform during Q1 2025, while maintaining a robust cash balance and preparing for international collaborations.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

QPM Energy Limited has announced a significant 31% upgrade to its Moranbah Gas Project's 2P reserves, now certified at 435PJ, reinforcing the asset's status as a tier 1 gas resource with substantial uncontracted volumes.

IPB Petroleum Limited has secured a crucial two-year extension on its WA-424-P permit in the Browse Basin, enabling continued exploration and development of its Gwydion asset while maintaining a solid cash position of AUD 1.487 million.

ADX Energy reported a 13% rise in Austrian production and a 15% increase in sales revenue for Q1 2025, while Welchau-1 well testing remains suspended pending legal review. The company also secured a key Italian gas exploration permit, positioning for growth across Europe.

FirstWave’s Q3 FY25 update reveals steady contract renewals alongside tighter cash reserves, as the cybersecurity firm advances strategic partnerships and operational efficiencies.

Carnegie Clean Energy has advanced its ACHIEVE Programme with a key contract for CETO deployment at the Basque Marine Energy Platform, securing milestone payments exceeding €1.5 million and launching a new Investor Hub to enhance shareholder engagement.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Pure Hydrogen Corporation has marked significant progress in its clean energy transition, delivering Australia's first hydrogen fuel cell garbage truck and securing multi-million dollar contracts with industry leaders TOLL Transport and Heidelberg Materials.

Sparc Technologies has progressed to Stage 2 of its Sparc Hydrogen joint venture with pilot plant commissioning slated for mid-2025, while also securing its first patent for photocatalytic water splitting technology in Morocco. Concurrently, its graphene-based additive ecosparc® demonstrates promising field trial results, underpinning commercial momentum.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.